Small‐Molecule Protein Kinase Inhibitors Approved by the U.S. FDA as Anticancer Agents From 2021 to 2025
Medicinal Research Reviews · 16.11.2026
DOI: 10.1002/med.70122 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 16.11.2026. Verfasst von Qi-Qi Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit nennt 174 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Protein kinases coordinate cellular proliferation, differentiation, survival, metabolism, and stress responses, and dysregulated kinase signalingf is a defining feature of many malignancies. From 2021 through 2025, the U.S. Food and Drug Administration (U.S. FDA) approved 26 small‐molecule kinase inhibitors for cancer therapy, extending precision treatment across non–small‐cell lung cancer, hematologic malignancies, breast and ovarian cancers, cholangiocarcinoma, renal cell carcinoma, glioma, and other kinase‐driven tumors. The approved agents illustrate advances in medicinal chemistry and translational pharmacology that include covalent inhibitors such as sotorasib and futibatinib, mutation‐selective inhibitors such as taletrectinib and zongertinib, allosteric inhibitors such as asciminib and mirdametinib, and multitarget or combination strategies such as avutometinib plus defactinib. Improvements in central nervous system exposure, mutant selectivity, dosing durability, and biomarker‐defined patient selection have broadened clinical utility. This Review integrates the discovery background, mechanism of action, synthetic route, pharmacological properties, clinical efficacy, safety, and regulatory context of these agents. It also evaluates acquired resistance, target‐related and off‐target toxicities, heterogeneous evidence supporting accelerated approvals, and the uncertain translation of biochemical potency into durable survival benefit. Successful kinase drug development therefore requires molecular design to be aligned with clinically achievable exposure, validated biomarkers, resistance surveillance, and confirmatory evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
- The First Clinical Medical College, Zhengzhou University, Zhengzhou, Henan, China.
- The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Yan Xu, Jian Song, Sai-Yang Zhang
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Zitieren
APA
Chen, Q. Q., Li, Y. B., Niu, J. B., Huang, C. Z., Xu, Y., Song, J., & Zhang, S. Y. (2026). Small‐Molecule Protein Kinase Inhibitors Approved by the U.S. FDA as Anticancer Agents From 2021 to 2025. Medicinal Research Reviews. https://doi.org/10.1002/med.70122
Vancouver
Chen QQ, Li YB, Niu JB, Huang CZ, Xu Y, Song J, et al. Small‐Molecule Protein Kinase Inhibitors Approved by the U.S. FDA as Anticancer Agents From 2021 to 2025. Medicinal Research Reviews. 2026. doi:10.1002/med.70122
BibTeX
@article{Chen2026,
author = {Chen, Qi-Qi and Li, Yan-Bo and Niu, Jin-Bo and Huang, Chen-Zheng and Xu, Yan and Song, Jian and Zhang, Sai-Yang},
title = {Small‐Molecule Protein Kinase Inhibitors Approved by the U.S. FDA as Anticancer Agents From 2021 to 2025},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70122}
}
EUVIMED